386 related articles for article (PubMed ID: 25613308)
21. Alteplase for Stroke With Unknown Onset Time in Chronic Kidney Disease: A Pooled Analysis of Individual Participant Data.
Miwa K; Koga M; Jensen M; Inoue M; Yoshimura S; Fukuda-Doi M; Boutitie F; Ma H; Ringleb PA; Wu O; Schwamm LH; Warach S; Hacke W; Davis SM; Donnan GA; Gerloff C; Thomalla G; Toyoda K;
Stroke; 2022 Nov; 53(11):3295-3303. PubMed ID: 35997023
[TBL] [Abstract][Full Text] [Related]
22. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
[TBL] [Abstract][Full Text] [Related]
23. Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study.
Wang X; Song L; Yang J; Sun L; Moullaali TJ; Sandset EC; Delcourt C; Lindley RI; Robinson TG; Minhas JS; Arima H; Chalmers J; Kim JS; Sharma V; Wang JG; Pontes-Neto O; Lavados PM; OlavarrÃa VV; Lee TH; Levi C; Martins SO; Thang NH; Anderson CS;
Cerebrovasc Dis; 2019; 48(3-6):207-216. PubMed ID: 31812956
[TBL] [Abstract][Full Text] [Related]
24. Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012.
Tong X; George MG; Yang Q; Gillespie C
Int J Stroke; 2014 Aug; 9(6):728-34. PubMed ID: 24024962
[TBL] [Abstract][Full Text] [Related]
25. Thrombolysis outcomes according to arterial characteristics of acute ischemic stroke by alteplase dose and blood pressure target.
Zhou Z; Xia C; Mair G; Delcourt C; Yoshimura S; Liu X; Chen Z; Malavera A; Carcel C; Chen X; Wang X; Al-Shahi Salman R; Robinson TG; Lindley RI; Chalmers J; Wardlaw JM; Parsons MW; Demchuk AM; Anderson CS
Int J Stroke; 2022 Jun; 17(5):566-575. PubMed ID: 34096413
[TBL] [Abstract][Full Text] [Related]
26. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?
Kent DM; Ruthazer R; Selker HP
Stroke; 2003 Feb; 34(2):464-7. PubMed ID: 12574561
[TBL] [Abstract][Full Text] [Related]
27. Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial.
Wang X; Robinson TG; Lee TH; Li Q; Arima H; Bath PM; Billot L; Broderick J; Demchuk AM; Donnan G; Kim JS; Lavados P; Lindley RI; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sharma VK; Thang NH; Wang JG; Woodward M; Anderson CS; Chalmers J;
JAMA Neurol; 2017 Nov; 74(11):1328-1335. PubMed ID: 28973174
[TBL] [Abstract][Full Text] [Related]
28. Thrombolysis for acute ischaemic stroke.
Wardlaw JM; Zoppo G; Yamaguchi T; Berge E
Cochrane Database Syst Rev; 2003; (3):CD000213. PubMed ID: 12917889
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial.
Li S; Wang X; Jin A; Liu G; Gu H; Li H; Campbell BCV; Fisher M; Yang Y; Wei Y; Wang J; Wang Y; Zhao X; Liu L; Li Z; Meng X; Wang Y
Stroke; 2024 Feb; 55(2):366-375. PubMed ID: 38152962
[TBL] [Abstract][Full Text] [Related]
30. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
[TBL] [Abstract][Full Text] [Related]
31. Safety of standard-dose (.9-mg/kg) alteplase intravenous thrombolysis for acute ischemic stroke in Afro-Caribbeans, French West Indies.
Chausson N; Olindo S; Joux J; Saint-Vil M; Aveillan M; Smadja D
J Stroke Cerebrovasc Dis; 2014 Aug; 23(7):1776-80. PubMed ID: 24957315
[TBL] [Abstract][Full Text] [Related]
32. In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous?
Kent DM; Hinchey J; Price LL; Levine SR; Selker HP
Stroke; 2004 May; 35(5):1141-6. PubMed ID: 15087567
[TBL] [Abstract][Full Text] [Related]
33. Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Amlie-Lefond C; Shaw DWW; Cooper A; Wainwright MS; Kirton A; Felling RJ; Abraham MG; Mackay MT; Dowling MM; Torres M; Rivkin MJ; Grabowski EF; Lee S; Kurz JE; McMillan HJ; Barry D; Lee-Eng J; Ichord RN
Stroke; 2020 Feb; 51(2):542-548. PubMed ID: 31842706
[TBL] [Abstract][Full Text] [Related]
34. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
[TBL] [Abstract][Full Text] [Related]
35. Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database.
Nagel S; Wang X; Carcel C; Robinson T; Lindley RI; Chalmers J; Anderson CS;
Stroke; 2018 Jun; 49(6):1407-1411. PubMed ID: 29777016
[TBL] [Abstract][Full Text] [Related]
36. Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial.
Koga M; Yamamoto H; Inoue M; Asakura K; Aoki J; Hamasaki T; Kanzawa T; Kondo R; Ohtaki M; Itabashi R; Kamiyama K; Iwama T; Nakase T; Yakushiji Y; Igarashi S; Nagakane Y; Takizawa S; Okada Y; Doijiri R; Tsujino A; Ito Y; Ohnishi H; Inoue T; Takagi Y; Hasegawa Y; Shiokawa Y; Sakai N; Osaki M; Uesaka Y; Yoshimura S; Urabe T; Ueda T; Ihara M; Kitazono T; Sasaki M; Oita A; Yoshimura S; Fukuda-Doi M; Miwa K; Kimura K; Minematsu K; Toyoda K;
Stroke; 2020 May; 51(5):1530-1538. PubMed ID: 32248771
[TBL] [Abstract][Full Text] [Related]
37. Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke.
Huang X; Moreton FC; Kalladka D; Cheripelli BK; MacIsaac R; Tait RC; Muir KW
Stroke; 2015 Dec; 46(12):3543-6. PubMed ID: 26514192
[TBL] [Abstract][Full Text] [Related]
38. Unequal access to treatment with intravenous alteplase for women with acute ischemic stroke.
de Ridder I; Dirks M; Niessen L; Dippel D;
Stroke; 2013 Sep; 44(9):2610-2. PubMed ID: 23887843
[TBL] [Abstract][Full Text] [Related]
39. Imaging negative stroke: diagnoses and outcomes in intravenous tissue plasminogen activator-treated patients.
Spokoyny I; Raman R; Ernstrom K; Meyer BC; Hemmen TM
J Stroke Cerebrovasc Dis; 2014; 23(5):1046-50. PubMed ID: 24103663
[TBL] [Abstract][Full Text] [Related]
40. Increased benefit of alteplase in patients with ischemic stroke and a high body temperature.
de Ridder I; den Hertog H; van Gemert M; Dippel D; van der Worp B;
Cerebrovasc Dis; 2013; 35(1):60-3. PubMed ID: 23428998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
